Juvenile idiopathic arthritis

Clinical Immunology: Principles and Practice: Fourth Edition

Volumn , Issue , 2013, Pages 637-647

  Cron, Randy Q ^a   Weiser, Peter ^b   Beukelman, Timothy ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899650413     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7234-3691-1.00066-0     Document Type: Chapter

References (54)

1. Weiss J.E., Ilowite N.T. Juvenile idiopathic arthritis. Rheum Dis Clin North Am 2007, 33(3):441-470. vi.
2. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31(2):390-392.
3. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9(5):A319-A324.
4. Ringold S., Cron R.Q. The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic. Pediatr Rheumatol Online J 2009, 7:11.
5. Ravelli A., Varnier G.C., Oliveira S., et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011, 63(1):267-275.
6. Prahalad S., Glass D.N. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008, 6:11.
7. Vastert S.J., Kuis W., Grom A.A. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009, 23(5):655-664.
8. Goldbach-Mansky R., Kastner D.L. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009, 124(6):1141-1149. quiz 50-1.
9. Grom A.A., Mellins E.D. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010, 22(5):561-566.
10. Behrens E.M. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?. Autoimmun Rev 2008, 7(4):305-308.
11. Colbert R.A., DeLay M.L., Klenk E.I., Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev 2010, 233(1):181-202.
12. de Vries R. Genetics of rheumatoid arthritis: time for a change!. Curr Opin Rheumatol 2011, 23(3):227-232.
13. Angeles-Han S., Prahalad S. The genetics of juvenile idiopathic arthritis: what is new in 2010?. Curr Rheumatol Rep 2010, 12(2):87-93.
14. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009, 33(1):3-11.
15. Prakken B.J., Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol 2009, 23(5):599-608.
16. Stoll M.L. Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol 2011, 29(2):322-330.
17. Steere A.C., Drouin E.E., Glickstein L.J. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011, 52(Suppl. 3):s259-s265.
18. Davies K., Stiehm E.R., Woo P., Murray K.J. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. J Rheumatol 2001, 28(10):2326-2334.
19. Wright T., Cron R.Q. Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis. J Clin Rheumatol 2007, 13(4):205-210.
20. Mor-Vaknin N., Kappes F., Dick A.E., et al. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum 2011, 63(2):556-567.
21. Syed R.H., Gilliam B.E., Moore T.L. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep 2008, 10(2):156-163.
22. Ochs H.D., Gambineri E., Torgerson T.R. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007, 38(1-3):112-121.
23. Cron R.Q. A signal achievement in the treatment of arthritis. Arthritis Rheum 2005, 52(8):2229-2232.
24. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009, 9(12):883-889.
25. Nistala K., Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009, 48(6):602-606.
26. Shenoi S., Wallace C.A. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010, 12(6):367-377.
27. Pascual V., Allantaz F., Patel P., et al. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 2008, 223:39-59.
28. Miettunen P.M., Narendran A., Jayanthan A., et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011, 50(2):417-419.
29. Boros C., Whitehead B. Juvenile idiopathic arthritis. Aust Fam Physician 2010, 39(9):630-636.
30. Houghton K.M. Review for the generalist: evaluation of pediatric hip pain. Pediatr Rheumatol Online J 2009, 7:10.
31. Hashkes P.J., Laxer R.M. Medical treatment of juvenile idiopathic arthritis. JAMA 2005, 294(13):1671-1684.
32. Stoll M.L., Nigrovic P.A. Subpopulations within juvenile psoriatic arthritis: a review of the literature. Clin Dev Immunol 2006, 13(2-4):377-380.
33. Colbert R.A. Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010, 6(8):477-485.
34. McGhee J.L., Kickingbird L.M., Jarvis J.N. Clinical utility of antinuclear antibody tests in children. BMC Pediatr 2004, 4:13.
35. McKay G.M., Cox L.A., Long B.W. Imaging juvenile idiopathic arthritis: assessing the modalities. Radiol Technol 2010, 81(4):318-327.
36. Kump L.I., Castaneda R.A., Androudi S.N., et al. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006, 113(10):1874-1877.
37. Cassidy J., Kivlin J., Lindsley C., Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006, 117(5):1843-1845.
38. Arabshahi B., Cron R.Q. Temporomandibular joint arthritis in juvenile idiopathic arthritis: the forgotten joint. Curr Opin Rheumatol 2006, 18(5):490-495.
39. Cannizzaro E., Schroeder S., Muller L.M., et al. Temporomandibular joint involvement in children with juvenile idiopathic arthritis. J Rheumatol 2011, 38(3):510-515.
40. Beresford M.W. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs 2011, 13(3):161-173.
41. Hayward K., Wallace C.A. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009, 11(1):216.
42. Cush J.J. Early rheumatoid arthritis-is there a window of opportunity?. J Rheumatol Suppl 2007, 80:1-7.
43. Prince F.H., Otten M.H., van Suijlekom-Smit L.W. Diagnosis and management of juvenile idiopathic arthritis. BMJ 2010, 341:c6434.
44. Beukelman T., Patkar N.M., Saag K.G., et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011, 63(4):465-482.
45. Wallace C.A., Ruperto N., Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31(11):2290-2294.
46. Scott C., Meiorin S., Filocamo G., et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol 2010, 28(5):774-781.
47. Rigby W.F. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?. Nat Clin Pract Rheumatol 2007, 3(4):227-233.
48. Cron R.Q., Beukelman T. Guilt by association-what is the true risk of malignancy in children treated with etanercept for JIA?. Pediatr Rheumatol Online J 2010, 8:23.
49. Nigrovic P.A., Mannion M., Prince F.H., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63(2):545-555.
50. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371(9617):998-1006.
51. Haibel H., Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?. Curr Opin Rheumatol 2010, 22(4):388-392.
52. Deane S., Selmi C., Teuber S.S., Gershwin M.E. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol 2010, 153(2):109-120.
53. Simonini G., Cantarini L., Bresci C., et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010, 9(10):674-683.
54. Foell D., Wulffraat N., Wedderburn L.R., et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010, 303(13):1266-1273.